Hot Features
Premium
Level up your trading with our powerful tools and real-time insights all in one place.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| DaVita Inc | DVA | NYSE | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 139.01 | 19:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 139.01 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 71.51 - 141.54 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| - | 0 | US$ 139.01 | USD |
DaVita (DVA) Options Flow Summary
DaVita Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 12.2B | 87.70M | - | 12.14B | 691.54M | 7.89 | 17.64 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
DaVita News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical DVA Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 133.10 | 139.48 | 130.96 | 136.17 | 679,898 | 5.91 | 4.44% |
| 1 Month | 135.15 | 139.48 | 125.64 | 132.75 | 529,036 | 3.86 | 2.86% |
| 3 Months | 112.09 | 141.54 | 108.76 | 129.38 | 818,373 | 26.92 | 24.02% |
| 6 Months | 76.92 | 141.54 | 76.2346 | 111.40 | 931,345 | 62.09 | 80.72% |
| 1 Year | 90.16 | 141.54 | 71.51 | 102.40 | 896,352 | 48.85 | 54.18% |
| 3 Years | 117.29 | 141.54 | 65.28 | 99.66 | 792,431 | 21.72 | 18.52% |
| 5 Years | 55.51 | 141.54 | 43.40 | 85.16 | 1,060,752 | 83.50 | 150.42% |
DaVita Description
| DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government ( primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business. |
